Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody

摘要: Abstract In phase II trials, the anti-epidermal growth factor receptor antibody IMC-C225 did not appear to significantly exacerbate common toxicities associated with cytotoxic chemotherapy when combined standard anticancer treatments in patients colorectal cancer, squamous cell carcinoma of head and neck, or pancreatic cancer. The most treatment-related adverse events reported during therapy were an acne-like rash hypersensitivity reactions. appeared as a sterile, suppurative form folliculitis, commonly starting on face, scalp, chest, upper back. It resolved without scarring once treatment was stopped. Notably, appearance rash, particularly grade 3, higher responses refractory reactions occurred less often than rash. They responded after first dose. summary, is generally well tolerated single agent radiotherapy possesses manageable toxicity profile. Semin Oncol 29 (suppl 14):55-60. Copyright 2002, Elsevier Science (USA). All rights reserved.